Genesis Molecular AI

Genesis Molecular AI – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego and offices in New York – is pioneering foundation models for molecular AI to unlock a new era of drug design and development. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery.

The GEMS platform integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI platform collaborations across a range of therapeutic areas including Gilead (2024), and Incyte (2025).

Genesis has raised over $300M in funding from top AI, technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. To learn more about Genesis Molecular AI, or current employment opportunities, please visit our website.